Savara Inc (SVRA) Sees Significant Growth in Short Interest

Savara Inc (NASDAQ:SVRA) was the recipient of a large increase in short interest during the month of May. As of May 31st, there was short interest totalling 898,745 shares, an increase of 43.6% from the May 15th total of 625,736 shares. Based on an average daily volume of 183,831 shares, the days-to-cover ratio is presently 4.9 days. Currently, 3.8% of the shares of the company are sold short.

SVRA opened at $13.23 on Friday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 16.28 and a current ratio of 16.28. Savara has a twelve month low of $5.07 and a twelve month high of $17.19. The stock has a market capitalization of $370.65 million, a PE ratio of -7.52 and a beta of 0.05.

Savara (NASDAQ:SVRA) last posted its earnings results on Wednesday, May 9th. The company reported ($0.32) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.01). analysts expect that Savara will post -1.37 earnings per share for the current year.



Several brokerages have issued reports on SVRA. Canaccord Genuity set a $25.00 price target on shares of Savara and gave the company a “buy” rating in a report on Friday, February 16th. BidaskClub raised shares of Savara from a “sell” rating to a “hold” rating in a report on Wednesday. ValuEngine lowered shares of Savara from a “sell” rating to a “strong sell” rating in a report on Thursday, March 1st. Zacks Investment Research lowered shares of Savara from a “hold” rating to a “sell” rating in a report on Wednesday, May 30th. Finally, Evercore ISI began coverage on shares of Savara in a report on Friday, June 8th. They issued an “outperform” rating and a $40.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $25.44.

In other Savara news, Director Yuri Pikover purchased 3,734 shares of the stock in a transaction on Thursday, March 29th. The shares were purchased at an average price of $9.00 per share, with a total value of $33,606.00. Following the acquisition, the director now directly owns 153,734 shares of the company’s stock, valued at approximately $1,383,606. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Robert N. Neville sold 2,737 shares of the business’s stock in a transaction on Friday, June 8th. The shares were sold at an average price of $12.13, for a total transaction of $33,199.81. Following the completion of the sale, the chief executive officer now directly owns 402,648 shares in the company, valued at approximately $4,884,120.24. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 47,055 shares of company stock valued at $569,209. Corporate insiders own 6.10% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the company. Sectoral Asset Management Inc bought a new stake in shares of Savara in the 4th quarter worth about $2,374,000. VHCP Management II LLC bought a new stake in shares of Savara in the 4th quarter worth about $18,691,000. Brown Advisory Inc. bought a new stake in shares of Savara in the 4th quarter worth about $2,098,000. Consonance Capital Management LP bought a new stake in shares of Savara in the 4th quarter worth about $40,899,000. Finally, Virtu Financial LLC bought a new stake in shares of Savara in the 4th quarter worth about $464,000. 40.98% of the stock is currently owned by institutional investors and hedge funds.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply